Search Cancer Clinical Trials

The Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
12 results
  • Prostate Cancer

19-618          Phase I

A Phase 1 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN424 in Patients with Advanced Prostate Cancer Refractory to Androgen Therapy (View details on

  • Prostate Cancer

19-060          Phase I

A phase 1, open-label, dose escalation clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARV-110 in patients with metastatic castration-resistant prostate cancer who have progressed on at least two prior systemic therapies (View details on

  • Prostate Cancer

18-117          Phase II

A Phase 2 Study of PCM-075 in Combination with Abiraterone and Prednisone in Subjects with Metastatic Castration-Resistant Prostate Cancer (View details on

  • Prostate Cancer

19-241          Phase III

A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer (View details on

  • Endometrial Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Ovarian Cancer, Lymphoma

18-441          Phase I

An open-label, first-in-human, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose and / or recommended Phase II dose of the ATR inhibitor BAY 1895344 in patients with advanced solid tumors and lymphomas (View details on

  • Prostate Cancer

19-267          N/A

Continuing Access to the Tyrosine Kinase Inhibitor Of VEGFR-2, AG-013736 (A406) For Patients Previously Receiving AG-013736 In Clinical Trials (View details on

  • Bladder Cancer, Prostate Cancer, Lung Cancer, Melanoma, Kidney Cancer, Breast Cancer

16-150          Phase I

Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers (View details on

  • Lung Cancer, Metastatic/Advanced Cancer, Prostate Cancer, Ovarian Cancer, Breast Cancer

17-687          Phase II

Phase 1b/2 Study To Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Advanced Or Metastatic Solid Tumors (View details on

Showing 1 - 10 of 12 results